原发性肝癌病人血清高尔基蛋白73、铁蛋白、甲胎蛋白联合检测的早期诊断价值分析

目的:分析原发性肝癌病人早期经血清高尔基蛋白73(GP73)、铁蛋白(SF)、甲胎蛋白(AFP)联合检测的诊断价值。方法:选取原发性肝癌病人72例作为观察组,同期选取健康体检人员60名作为对照组。检测2组受试者GP73、SF、AFP三项指标,对三项指标与原发性肝癌发病的相关性作logistic回归分析,比较三种指标单独及联合检测原发性肝癌的敏感性与特异性。结果:观察组病人GP73、SF、AFP指标均明显高于对照组(P<0.01)。回归分析结果显示,GP73、SF、AFP水平高均为原发性肝癌的危险因素(P<0.05~P<0.01)。GP73、SF、AFP指标单独检测诊断原发性肝癌的敏感性分别为69.44%、66.67%、70.83%,特异性分别为96.67%、91.67%、95.00%。三项联合检测的敏感性为98.61%,高于单独检测;特异性为83.33%,低于单独检测。结论:GP73、SF、AFP是临床诊断原发性肝癌的重要血清学指标,与单项检测相比,三项联合检测提高了诊断敏感性。

甲胎蛋白阴性原发性肝癌患者C反应蛋白和补体水平及其临床应用价值

目的探讨甲胎蛋白阴性原发性肝癌(PHC)患者血清C反应蛋白(CRP)、补体C3和C4水平及其临床应用价值。方法纳入72例甲胎蛋白阴性PHC患者(甲胎蛋白阴性组)、73例甲胎蛋白阳性PHC患者(甲胎蛋白阳性组)和73例健康志愿者(对照组)。比较3组血清CRP、补体C3及C4水平,并比较不同病理分型PHC患者CRP、C3、C4水平。结果对照组、甲胎蛋白阳性组、甲胎蛋白阴性组血清CRP和C3水平依次升高(P<0.05),且甲胎蛋白阳性组及阴性组C3、C4、CRP阳性率均高于对照组(均P<0.05)。不同病理分型的PHC患者血清CRP、C3、C4水平比较,差异均无统计学意义(P>0.05)。结论相对于正常人及甲胎蛋白阳性的PHC患者,甲胎蛋白阴性PHC者血清CRP和C3水平均异常升高,两者对血清甲胎蛋白阴性肝癌的早期诊断有一定的临床价值。

ERCC1基因多态性与肝癌的相关性研究

目的探讨核酸切除修复基因1(ERCC1)的单核苷酸多态性(SNP)与肝癌易感性的相关性,并研究ERCC1基因多态性和肝癌组织ERCC1蛋白表达的关系。方法本研究纳入肝细胞癌患者及对照组各65例,采用SNa Pshot技术对ERCC1基因rs735482,rs1046282,rs3212948三个多态性位点进行基因分析,免疫组织化学方法检测肝癌组织ERCC1蛋白表达,卡方检验分析上述三个多态性位点基因型在研究对象中的分布情况与及其与肝癌组织ERCC1蛋白表达的关系进行分析,非条件Logistic回归分析法对以上三个SNP位点等位基因和基因型频率与肝癌的发病风险关系进行分析,以P <0. 05表明存在统计学差异。结果对照组中三个多态性位点基因型分布均符合哈温平衡规律。病例组ERCC1基因rs1046282位点基因型频数分别为:CC为8(12. 31%),CT为30(46. 15%),TT为27(41. 54%);对照组该位点基因型频率分布:CC为22(33. 85%),CT为25(38. 46%),TT为18(27. 69%),CC、CT、TT基因型在两组中的频数分布差异具有统计学意义P=0. 012;T等位基因在病例组中的分布频率高于对照组(P=0. 004);与CC基因型比较,携带至少1个突变等位基因T(CT+TT)的个体发生肝癌的风险增加了2. 218倍(P=0. 017)。rs3212948和rs735482位点单核苷酸多态性与肝癌患病风险性不存在相关性(P> 0. 05),以上三个位点的单核苷酸多态性与肝癌组织ERCC1蛋白的表达无相关性(P>0. 05)。结论 ERCC1基因rs1046282位点多态性与肝癌易感性相关,且携带突变T等位基因比携带C等位基因患肝癌的风险率高。尚未发现ERCC1基因rs735482,rs3212948位点突变与肝癌的发病风险存在相关性,这三个位点单核苷酸多态性与肝癌组织ERCC1蛋白表达不相关。

基于ANSYS ICEPAK的混合扰流微通道冷板的研究与优化

微通道是一种新型高效的散热技术,可以在有限的尺寸内极大地提高系统的对流换热能力.本文通过ICEPAK软件仿真模拟不同材料的冷板,分别对比蛇形、常规微通道、断齿微通道和扰流微通道冷板对散热性能的影响,得到不同通道冷板的综合性能.研究结果具有工程应用价值,为高热耗的电子设备散热问题提供参考.

β-Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency——A Randomized,Placebo-Controlled,and Double-Blinded Trial

Objective:To test the hypothesis thatβ-glucan enhances protective qi(PQi),an important Chinese medicine(CM)concept which stipulates that a protective force circulates throughout the body surface and works as the first line of defense against"external pernicious influences".Methods:A total of 138 participants with PQi deficiency(PQD)were randomized to receiveβ-glucan(200 mg daily)or placebo for 12 weeks.Participants’PQi status was assessed every 2 weeks via conventional diagnosis and a standardized protocol from which a PQD severity and risk score was derived.Indices of participants’immune and general health status were also monitored,including upper respiratory tract infection(URTI),saliva secretory Ig A(s Ig A),and self-reported measures of physical and mental health(PROMIS).Results:PQi status was not significantly different between theβ-glucan and placebo treatment groups at baseline but improved significantly in theβ-glucan(vs.placebo)group in a time-dependent manner.The intergroup differences[95%confidence interval(CI)]in severity score(scale:1-5),risk score(scale:0-1),and proportion of PQD participants(%)at finish line was 0.49(0.35-0.62),0.48(0.35-0.61),and 0.36(0.25-0.47),respectively.Additionally,β-glucan improved URTI symptom(scale:1-9)and PROMIS physical(scale:16.2-67.7)and mental(scale:21.2-67.6)scores by a magnitude(95%CI)of 1.0(0.21-1.86),5.7(2.33-9.07),and 3.0(-0.37-6.37),respectively,over placebo.Conclusions:β-Glucan ameliorates PQi in PQD individuals.By using stringent evidence-based methodologies,our study demonstrated that Western medicine-derived remedies,such asβ-glucan,can be employed to advance CM therapeutics.(Clinical Trial.Gov registry:NCT03782974)

Proof-of-Concept and Feasibility Study to Evaluate the Effect of β-Glucan on Protective Qi Deficiency in Adults

Objective:To preliminarily explore the potential effect ofβ-glucan on Chinese medicine(CM)concept protective qi deficiency(PQD),and the methodology for future definitive studies.Methods:To have a standardized assessment of PQD,a list of 13 potentially PQD-relevant parameters were firstly created,each with defined quantitative or categorial scales.Using the data from 37 participants with(21 cases)or without(16 cases)PQD,multivariate logistic modeling was conducted to create a preliminary diagnostic PQD risk score.Subsequently,21 participants diagnosed with PQD were treated withβ-glucan in a dose of 200 mg/day for 8 weeks.Data were collected for trial acceptability measures(rate of recruitment,withdrawal,and compliance),and the participants were assessed for PQD status at baseline and every 2 weeks thereafter.Results:The preliminary logistic model consisted of 3 parameters(low voice and apathy,aversion to wind and cold,and Cun pulse).The resulting risk score demonstrated a degree of PQD-predicting accuracy that,as evaluated by statistical(discrimination and classification)methods,was higher than those obtained from any of the individual candidate parameters.The 21 PQD participants treated withβ-glucan demonstrated good receptibility and a time-dependent improvement in PQD status as evidenced by the decrease of PQD participant to 9.5%at the end of study.Conclusions:This study demonstrated the effect of proof-of-concept ofβ-glucan on improving PQD and the proof-of-concept of a multivariate-model-derived diagnostic PQD risk score.It also indicated feasibility for future definitive studies.Studies like this embody an innovative approach that uses therapies derived from the mainstream biomedicine to enrich therapeutics guided by CM principle.(Trial registration No.NCT03829228).